Analysts Set Vaxcyte, Inc. (NASDAQ:PCVX) Price Target at $145.71

Shares of Vaxcyte, Inc. (NASDAQ:PCVX) have been given a consensus rating of “Buy” by the eight analysts that are currently covering the company, Marketbeat Ratings reports. Eight research analysts have rated the stock with a buy recommendation. The average 12-month price target among analysts that have covered the stock in the last year is $145.71.

A number of brokerages have recently issued reports on PCVX. Cantor Fitzgerald restated an “overweight” rating on shares of Vaxcyte in a research note on Wednesday, November 6th. Needham & Company LLC restated a “buy” rating and set a $140.00 price objective on shares of Vaxcyte in a research note on Wednesday, November 6th. Finally, The Goldman Sachs Group initiated coverage on Vaxcyte in a research report on Friday, December 20th. They issued a “buy” rating and a $135.00 target price for the company.

Vaxcyte Trading Up 2.0 %

Vaxcyte stock opened at $86.51 on Friday. Vaxcyte has a 52 week low of $58.10 and a 52 week high of $121.06. The stock has a market cap of $10.78 billion, a P/E ratio of -18.81 and a beta of 0.98. The stock has a 50 day moving average of $87.46 and a 200-day moving average of $94.42.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.83) EPS for the quarter, beating analysts’ consensus estimates of ($1.10) by $0.27. During the same quarter in the prior year, the company earned ($0.91) EPS. As a group, equities analysts predict that Vaxcyte will post -4.21 earnings per share for the current fiscal year.

Insider Buying and Selling at Vaxcyte

In related news, CEO Grant Pickering sold 2,366 shares of the stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $103.89, for a total value of $245,803.74. Following the sale, the chief executive officer now owns 137,398 shares of the company’s stock, valued at $14,274,278.22. This trade represents a 1.69 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Jim Wassil sold 8,000 shares of Vaxcyte stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $83.66, for a total transaction of $669,280.00. Following the completion of the sale, the chief operating officer now owns 205,695 shares in the company, valued at approximately $17,208,443.70. This represents a 3.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 70,982 shares of company stock worth $6,341,485 over the last ninety days. Company insiders own 3.10% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Blue Trust Inc. boosted its position in shares of Vaxcyte by 33.5% during the third quarter. Blue Trust Inc. now owns 371 shares of the company’s stock worth $42,000 after buying an additional 93 shares during the period. Nisa Investment Advisors LLC increased its position in Vaxcyte by 5.2% in the 3rd quarter. Nisa Investment Advisors LLC now owns 2,209 shares of the company’s stock valued at $252,000 after acquiring an additional 110 shares during the period. CIBC Asset Management Inc raised its stake in Vaxcyte by 3.6% during the 3rd quarter. CIBC Asset Management Inc now owns 3,136 shares of the company’s stock valued at $358,000 after acquiring an additional 110 shares in the last quarter. Riverview Trust Co acquired a new position in Vaxcyte during the 3rd quarter worth $27,000. Finally, Amalgamated Bank grew its stake in shares of Vaxcyte by 8.6% in the third quarter. Amalgamated Bank now owns 4,081 shares of the company’s stock worth $466,000 after purchasing an additional 322 shares in the last quarter. Institutional investors own 96.78% of the company’s stock.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.